2.59 (-%)
As of Oct 31, 2024
Source:
iBio, Inc is a preclinical stage biotechnology company leveraging the power of Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies. Our proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
Country | United States |
Headquarters | bryan, new york |
Phone Number | 302 355-0650 |
Industry | manufacturing |
CEO | Martin Brenner |
Website | http://www.ibioinc.com |